Scribe Therapeutics CFO David Parrot reports $ 39,990 common stock acquisitionPUBT·2 hours agoSCTX-12.38%
Scribe Therapeutics adopts amended and restated bylaws effective at IPO closePUBT·6 hours agoSCTX-12.38%
U.S. stock market update: Scribe Therapeutics down 12.03%, stock price pressured by clinical delay in gene editingPrice Alert·10 hours agoSCTX-12.38%
